Diagnosis and Treatment of Patients with Autoimmune Bullous Disorders in Germany

Enno Schmidt*, Detlef Zillikens

*Corresponding author for this work
8 Citations (Scopus)


In Germany, more than 2000 new patients per year have been calculated to be diagnosed with autoimmune blistering diseases. In a recent survey, the most frequently applied treatment regimens for bullous pemphigoid were class IV topical corticosteroids and oral prednisolone 0.5 mg or 1.0 mg/kg/d plus dapsone or azathioprine. For pemphigus, two-thirds of the clinics applied oral prednisolone at doses of 1.0 mg or 1.5 mg/kg/d and in more than 80% of departments, azathioprine was chosen as concomitant immunosuppressant. High-dose intravenous immunoglobulin, rituximab, and immunoadsorption are increasingly used for refractory patients. Treatment and diagnostic costs are covered by the health insurances when applied according to published expert recommendations.

Original languageEnglish
JournalDermatologic Clinics
Issue number4
Pages (from-to)663-671
Number of pages9
Publication statusPublished - 01.10.2011


Dive into the research topics of 'Diagnosis and Treatment of Patients with Autoimmune Bullous Disorders in Germany'. Together they form a unique fingerprint.

Cite this